Multicenter, randomized, open clinical study to evaluate efficacy and safety of Calcineurin inhibitors versus Mycophenolate in pediatric steroid-resistant nephrotic syndrome
Not Applicable
- Conditions
- Diseases of the genitourinary system
- Registration Number
- KCT0007983
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
More than 2 years old and under the 16 years old,
From Cohort of Korean pediatric nephrotic syndrome
Patients who did not get the remission, by steroid (for initial 4 weeks) and CNI (for next 3 months)
Exclusion Criteria
- Patients who were used secondary immunosuppressants (CPM, MMF, RTX, levamisole, mizoribin) for nephrotic syndrome within 4 weeks
- Secondary nephrotic syndrome
- Low C3 (< 60mg/dL)
- Patients who confirmed as genetic mutation associated with proteinuria or nephrotic syndrome
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The remission rate
- Secondary Outcome Measures
Name Time Method The complications of medication